Advicenne reports its financial results for the first half ended June 30, 2024 and updates on its activities

Regulatory news:

Advicenne (Euronext Growth Paris ALDVI – FR0013296746), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for patients with rare kidney diseases, today announces its half-year results ended June 30, 2024, approved by the Board of Directors on September 18, 2024. The half-year financial report is available on the Company’s website: www.advicenne.com.

Didier Laurens, CEO of Advicenne, commented: “During the first half of the year, we saw a steady increase in Sibnayal sales across Europe. Month after month, sales growth confirms the excellent acceptance of our treatment by patients and healthcare professionals. These favorable market trends, combined with our strict cost control, allow us to confirm our objective of achieving operating profitability by the end of 2024/early 2025. Finally, for the second half of the year, our teams remain committed to our strategic plan in the US, with further progress in our discussions with the FDA in the two indications for ADV7103 and concrete prospects for building commercial partnerships.”